Is Genprex struggling financially?

Yes, by its own account. Genprex told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

28/100

Fragile

Sector: Biotech/Pharma
Market cap: $3.2M
Source filing: 10-Q 13 May 2026
Balance sheet: 30 Jun 2026

Cash runway

5months

If the burn speeds up

Empty by Nov 2026
8months

If it eases off

Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$15.2M

Cash burned over the last 12 months

$26.7M

What Genprex told the SEC

…capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if Genprex is unable to continue as a going concern.

Genprex, Inc., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

Cash runway

The runway math

What Genprex told the SEC

What this means

Other Biotech/Pharma companies that filed the doubt